Table 1.

Baseline characteristics according to hs-TnI concentrations.

Characteristicshs-TnI concentrations, ng/L
<1.9 (n = 1417, 8.9%)1.9–3.8 (n = 4610, 29.1%)3.9–6.8 (n = 4244, 26.8%)6.9–26 (n = 4409, 27.8%)>26 (n = 1153, 7.3%)P value (5-way)P value for trend
Demographics
    Age, years, mean (SD)56.9 (10.4)60.6 (10.3)62.7 (10.6)63.0 (11.0)61.5 (11.4)<0.001
    ≥75 years, %5.09.114.115.913.7<0.001<0.001
    Male, %56.471.776.981.079.3<0.001<0.001
    White race88.386.084.283.379.3<0.001<0.001
    Weight, <60 kg, %11.08.47.67.37.6<0.001<0.001
CV history, %
    Diabetes mellitus19.823.026.828.032.5<0.001<0.001
    Hypertension60.768.372.673.371.2<0.001<0.001
    Current smoker24.323.420.818.616.4<0.001<0.001
    Prior CAD53.762.876.285.589.6<0.001<0.001
    Prior CVDa40.734.226.219.218.6<0.001<0.001
    Prior PAD24.225.626.625.023.20.100.49
    Prior HF1.93.16.213.417.7<0.001<0.001
    eGFR <60 mL · min−1 · (1.73 m2)−17.410.717.522.724.6<0.001<0.001
Qualifying eventb, %<0.001<0.001
    MI43.749.861.372.077.9
    Ischemic stroke37.630.420.212.611.4
    Symptomatic PAD18.719.818.515.410.7
Medications at enrollment, %
    Aspirin use89.290.692.494.494.7<0.001<0.001
    Thienopyridine use50.952.357.562.761.7<0.001<0.001
    Statin use88.386.887.189.389.9<0.0010.001
  • a CVD, cerebrovascular disease; HF, heart failure.

  • b If a patient had established qualifying disease in >1 vascular bed, the qualifying event was determined by the following hierarchical order: MI, ischemic stroke, symptomatic PAD.